Gliflozins better than GLP-1 agonists protect against recurrent nephrolithiasis in diabetes
Hyon Choi of Harvard Medical School and colleagues from Canada and the United States conducted an emulation of randomized trials and concluded that antidiabetic drugs from the SGLT1 inhibitor group (gliflozins)…